These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270 [TBL] [Abstract][Full Text] [Related]
3. The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. Ellis AC; Rosenfeld J CNS Drugs; 2004; 18(14):967-80. PubMed ID: 15584767 [TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
5. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020 [TBL] [Abstract][Full Text] [Related]
7. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against. Ludolph AC; Riepe MW Neurology; 1999; 53(8 Suppl 5):S46-9; discussion S55-7. PubMed ID: 10560638 [TBL] [Abstract][Full Text] [Related]
8. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Teng YD; Choi H; Huang W; Onario RC; Frontera WR; Snyder EY; Sabharwal S Neurosci Lett; 2006 Apr 10-17; 397(1-2):155-8. PubMed ID: 16388902 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562 [TBL] [Abstract][Full Text] [Related]
12. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118 [TBL] [Abstract][Full Text] [Related]
13. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. Gribkoff VK; Bozik ME CNS Neurosci Ther; 2008; 14(3):215-26. PubMed ID: 18801114 [TBL] [Abstract][Full Text] [Related]
14. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Cervetto C; Frattaroli D; Maura G; Marcoli M Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883 [TBL] [Abstract][Full Text] [Related]
15. Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future. Harikrishnareddy D; Misra S; Upadhyay S; Modi M; Medhi B Rev Neurosci; 2015; 26(2):161-81. PubMed ID: 25720096 [TBL] [Abstract][Full Text] [Related]
16. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Dyer AM; Smith A Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507 [TBL] [Abstract][Full Text] [Related]
18. Natural compounds used as therapies targeting to amyotrophic lateral sclerosis. Nabavi SF; Daglia M; D'Antona G; Sobarzo-Sánchez E; Talas ZS; Nabavi SM Curr Pharm Biotechnol; 2015; 16(3):211-8. PubMed ID: 25601606 [TBL] [Abstract][Full Text] [Related]
19. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087 [TBL] [Abstract][Full Text] [Related]
20. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Ng SK; Higashimori H; Tolman M; Yang Y Exp Neurol; 2015 May; 267():115-22. PubMed ID: 25779930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]